Displaying publications 61 - 80 of 294 in total

Abstract:
Sort:
  1. Fulltext Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population
    Riazalhosseini B, Mohamed Z, Apalasamy YD, Shafie NS, Mohamed R
    Biomed Rep, 2018 Sep;9(3):213-220.
    PMID: 30271596 DOI: 10.3892/br.2018.1126
    Interleukin-6 (IL-6) is a cytokine with a critical role in regulating the immune response to infectious disease. Studies have indicated that polymorphisms in the IL-6 gene may be linked to hepatitis B virus (HBV) infection. The purpose of the present study was to examine the association among IL-6 SNPs and haplotypes with HBV infection risk in a Malaysian population. A total of 1,246 Malaysian subjects with and without chronic hepatitis B were recruited for this study. Three IL-6 polymorphisms (rs2069837, rs1800796 and rs2066992) were genotyped using a Sequenom MassARRAY® platform. The results suggested that GC and CC genotypes of rs1800796 as well as GT and TT genotypes of rs2066992 were associated with protection against HBV infection (P<0.001). Furthermore, haplotypes GG and CT exhibited a significant association with protection against HBV (P=0.003 and =0.005, respectively); and haplotypes GG and CT exhibited a significant association with clearance of HBV infection (P=0.035 and =0.037, respectively). The present study indicates that two IL-6 SNPs (rs1800796 and rs2066992) are associated with clearance of chronic HBV or protection against HBV infection at allelic, genotypic and haplotypic levels.
    Matched MeSH terms: Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic
  2. Display of the antigenic region of Nipah virus nucleocapsid protein on hepatitis B virus capsid
    Yap WB, Tey BT, Alitheen NB, Tan WS
    J Biosci Bioeng, 2012 Jan;113(1):26-9.
    PMID: 22024533 DOI: 10.1016/j.jbiosc.2011.09.007
    The C-terminal domain of Nipah virus (NiV) nucleocapsid protein (NP₄₀₁₋₅₃₂) was inserted at the N-terminus and the immunodominant loop of hepatitis B core antigen (HBc). The stability of NP₄₀₁₋₅₃₂ increased tremendously when displayed on the HBc particles. These particles reacted specifically with the swine anti-NiV and the human anti-HBc antisera.
    Matched MeSH terms: Hepatitis B Antibodies/immunology; Hepatitis B Core Antigens/immunology; Hepatitis B virus/metabolism*
  3. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients
    Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al.
    Kidney Int, 2008 Apr;73(7):856-62.
    PMID: 18160963
    Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.
    Matched MeSH terms: Hepatitis B/prevention & control*; Hepatitis B Surface Antigens/blood*; Hepatitis B Vaccines/immunology*
  4. Negative chromatography purification of hepatitis B virus-like particles using poly(oligo(ethylene glycol) methacrylate) grafted cationic adsorbent
    Lee MF, Chan ES, Tan WS, Tam KC, Tey BT
    J Chromatogr A, 2015 Oct 9;1415:161-5.
    PMID: 26358561 DOI: 10.1016/j.chroma.2015.08.056
    Poly(oligo(ethylene glycol) methacrylate) (POEGMA), an inert polymer was grafted onto an anion exchange adsorbent for the exclusion of relatively larger hepatitis B virus-like particles (HB-VLPs) from the anion exchange ligand (Q) and at the same time this process allowed the selective adsorption of smaller size Escherichia coli host cell proteins (HCPs). The chain lengths of the POEGMA grafted were modulated by varying the amount of monomers used in the polymer grafting. The purification factor and yield of the HB-VLPs obtained from the flow-through of negative chromatography were 2.3 and 66.0±3.1%, respectively, when shorter chain length of POEGMA (SQ) was grafted. Adsorbent grafted with longer chain of POEGMA (LQ) excluded some HCPs that are larger in size together with the HB-VLPs, reducing the purity of the recovered HB-VLPs. Further heat-treatment of the flow-through pool from SQ followed by centrifugation increased the purity of heat stable HB-VLPs to 87.5±1.1%. Heat-treatment of the flow through sample resulted in thermal denaturation and aggregation of HCPs, while the heat stable HB-VLPs still remained intact as observed under a transmission electron microscope. The performance of the negative chromatography together with heat treatment in the purification of HB-VLPs is far better than the reported bind-and-elute techniques.
    Matched MeSH terms: Hepatitis B Core Antigens/genetics; Hepatitis B Core Antigens/isolation & purification*; Hepatitis B Core Antigens/metabolism; Hepatitis B virus/metabolism*
  5. Hepatitis B virus peptide inhibitors: solution structures and interactions with the viral capsid
    Muhamad A, Ho KL, Rahman MB, Tejo BA, Uhrín D, Tan WS
    Org Biomol Chem, 2015 Jul 28;13(28):7780-9.
    PMID: 26100394 DOI: 10.1039/c5ob00449g
    Hepatitis B virus (HBV) infection remains a health problem globally despite the availability of effective vaccines. In the assembly of the infectious virion, both the preS and S regions of the HBV large surface antigen (L-HBsAg) interact synergistically with the viral core antigen (HBcAg). Peptides preS and S based on the L-HBsAg were demonstrated as potential inhibitors to block the viral assembly. Therefore, the objectives of this study were to determine the solution structures of these peptides and study their interactions with HBcAg. The solution structures of these peptides were solved using (1)H, (13)C, and (15)N NMR spectroscopy. Peptide preS has several structured regions of β-turns at Ser7-Pro8-Pro9, Arg11-Thr12-Thr13 and Ser22-Thr23-Thr24 sequences whereas peptide S has only one structured region observed at Ser3-Asn4-His5. Both peptides contain bend-like structures surrounding the turn structures. Docking studies revealed that both peptides interacted with the immunodominant region of HBcAg located at the tip of the viral capsid spikes. Saturation Transfer Difference (STD) NMR experiments identified several aromatic residues in peptides preS and S that interact with HBcAg. This study provides insights into the contact regions of L-HBsAg and HBcAg at atomic resolution which can be used to design antiviral agents that inhibit HBV morphogenesis.
    Matched MeSH terms: Hepatitis B Core Antigens/isolation & purification; Hepatitis B Core Antigens/pharmacology; Hepatitis B Core Antigens/chemistry*; Hepatitis B virus/drug effects
  6. A cross-sectional study of hepatitis B immune status in Asian children in Singapore
    Quak SH, Singh R, Oon CJ, Wong HB
    Ann Trop Paediatr, 1982 Jun;2(2):53-6.
    PMID: 6185078
    A study of race-related distribution of hepatitis B markers was conducted in 458 children admitted consecutively to Singapore General Hospital. The positive rates for hepatitis B surface antigen (HBsAg) in Chinese, Malays and Indians were 11.2, 8.0 and 12.2% respectively and the corresponding figures for anti-HBs were 30.2, 12.0 and 14.6%. In Chinese children HBsAg prevalence was shown to be sex-related, being higher in males than females. The percentages of Chinese children positive for anti-HBs and anti-HBc were also higher than those of the Indians. This study confirmed that Singapore children were exposed to hepatitis B infection from early life. All three races were equally susceptible to this infection.
    Matched MeSH terms: Hepatitis B/epidemiology*; Hepatitis B Antibodies/analysis*; Hepatitis B Surface Antigens/analysis*
  7. Detection and precipitation of hepatitis B core antigen using a fusion bacteriophage
    Hasmoni SS, Yusoff K, Tan WS
    J Gen Appl Microbiol, 2005 Apr;51(2):125-31.
    PMID: 15942873
    The nucleocapsids of hepatitis B virus (HBV) are made of 180 or 240 subunits of core proteins or known as core antigens (HBcAg). A fusion bacteriophage bearing the WSFFSNI sequence that interacts tightly to HBcAg was employed as a diagnostic reagent for the detection of the antigen using the phage-enzyme-linked immunosorbent (phage-ELISA), dot blot and immunoprecipitation assays. The results from phage-ELISA and dot blot assay showed that as low as 10 ng of HBcAg can be detected optimally by 1.0x10(12) pfu/ml fusion M13 bacteriophage. The sensitivity of the dot blot assay corresponds with that of the phage-ELISA. HBcAg in HBV positive serum samples can also be detected using the fusion phage via the phage-ELISA and phage-dot blot assay. The phage cross-linked to cyanogen bromide (CNBr) activated agarose can also be used to precipitate HBcAg in bacterial lysate. The optimum amount of phage needed for cross-linking to 1 g of agarose is about 7.0x10(6) pfu/ml which could also precipitate purified and unpurified HBcAg in bacterial lysate. This study demonstrates the potential of fusion bacteriophage bearing the sequence WSFFSNI as a diagnostic reagent and a ligand for the detection and purification of HBcAg respectively.
    Matched MeSH terms: Hepatitis B/diagnosis*; Hepatitis B Core Antigens/isolation & purification*; Hepatitis B virus/isolation & purification*
  8. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia
    Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M
    Med Microbiol Immunol, 2005 May;194(3):163-8.
    PMID: 15834754
    The implementation of the Expanded Program of Immunization (EPI) in 1989 has dramatic impact on hepatitis B virus (HBV) infection in school children in Malaysia. A cross-sectional seroprevalence study of HBV infection in 190,077 school children aged 7-12 years from 1997 to 2003 showed a steady decline of HBV surface antigen (HBsAg) prevalence rate from 2.5% for children born in 1985 to 0.4% among school children born in 1996. The overall prevalence of HBsAg was 0.6%, 0.7% in males and 0.6% in females. Over 92.7% of school children had been vaccinated with HBV vaccine, in which 93.7% were vaccinated under the EPI and 6.3% on voluntary basis. The school children vaccinated under EPI had a 0.4% HBsAg carrier rate, which was significantly lower than school children vaccinated on a voluntary basis (HBsAg carrier rate 1.3%) and non-vaccinated school children (HBsAg carrier rate 2.7%), suggesting that HBV vaccination of infants was the most effective measure in preventing vertical transmission of HBV in the hyperendemic region.
    Matched MeSH terms: Hepatitis B/immunology*; Hepatitis B/epidemiology; Hepatitis B/prevention & control*; Hepatitis B Surface Antigens/blood
  9. Fulltext Weighted analysis of prevalence and risk factors of hepatitis B infection among antenatal mothers in Ipoh
    Shamsuddin K, Marmuji LZ
    Singapore Med J, 2010 Oct;51(10):800-5.
    PMID: 21103816
    Several strategies have been developed to reduce hepatitis B infections. These include antenatal screening, universal immunisation of newborns and immunoglobulin therapy for babies who are at risk. Antenatal screening for hepatitis B is not routinely performed, but all newborns in Malaysia are immunised against hepatitis B. We assessed the prevalence of hepatitis B and the factors associated with it among antenatal mothers in Ipoh. This information is useful in decision-making for future hepatitis B screening programmes for antenatal mothers, allowing for immunoglobulin therapies for newborns if their mother's hepatitis B virus (HBV) status is known.
    Matched MeSH terms: Hepatitis B/immunology*; Hepatitis B/epidemiology*; Hepatitis B/transmission; Hepatitis B virus/immunology
  10. Interpretation and application of virological testing including resistance in chronic hepatitis B
    Locarnini S
    Med J Malaysia, 2005 Jul;60 Suppl B:41-51.
    PMID: 16108173
    Matched MeSH terms: Hepatitis B virus/drug effects; Hepatitis B virus/genetics; Hepatitis B virus/immunology*; Hepatitis B, Chronic/diagnosis*; Hepatitis B, Chronic/genetics; Hepatitis B, Chronic/immunology
  11. Infectiousness of HBsAg carriers in Malaysia
    Ton SH, Yeoh KS, Lim WC, Noriah R, Cheong SK, Thanaletchimy N
    J Trop Med Hyg, 1995 Aug;98(4):277-80.
    PMID: 7636926
    HBV-DNA were analysed in 330 HBsAg-positive carriers in Malaysia by dot-blot hybridization and polymerase chain reaction. Seventy-three (22.12%) were positive for the virus. Of these, 65 (89%) were males and 8 (11%) were females. Statistically, there was no significant difference (P = 0.13). No significant decline in HBV-DNA with age in the Malay and Chinese males was observed (P = 0.2). Prevalence of HBV-DNA was higher in the Chinese carriers than in the Malay carriers for most age groups in both sexes. Sixty-one HBV-DNA-positive carriers were also positive for HBeAg. However, three individuals were positive only for anti-HBe, one was positive for both HBeAg and anti-HBe, and eight were negative for both HBeAg and anti-HBe. Fifty-seven were positive for HBeAg but negative for HBV-DNA. No relation was observed between raised alanine aminotransaminase and aspartate aminotransaminase levels and the presence of HBV-DNA (P = 0.4).
    Matched MeSH terms: Hepatitis B/ethnology; Hepatitis B/epidemiology*; Hepatitis B/transmission; Hepatitis B Surface Antigens/blood*; Hepatitis B virus/genetics
  12. Antenatal screening for hepatitis B in pregnant women
    Tan PE
    Malays J Pathol, 1988 Aug;10:79-83.
    PMID: 3252083
    Matched MeSH terms: Hepatitis B/prevention & control*
  13. Fulltext Hepatitis B Virus-Like Particle: Targeted Delivery of Plasmid Expressing Short Hairpin RNA for Silencing the Bcl-2 Gene in Cervical Cancer Cells
    Akwiditya MA, Yong CY, Yusof MT, Mariatulqabtiah AR, Ho KL, Tan WS
    Int J Mol Sci, 2021 Feb 26;22(5).
    PMID: 33652577 DOI: 10.3390/ijms22052320
    Gene therapy research has advanced to clinical trials, but it is hampered by unstable nucleic acids packaged inside carriers and there is a lack of specificity towards targeted sites in the body. This study aims to address gene therapy limitations by encapsidating a plasmid synthesizing a short hairpin RNA (shRNA) that targets the anti-apoptotic Bcl-2 gene using truncated hepatitis B core antigen (tHBcAg) virus-like particle (VLP). A shRNA sequence targeting anti-apoptotic Bcl-2 was synthesized and cloned into the pSilencer 2.0-U6 vector. The recombinant plasmid, namely PshRNA, was encapsidated inside tHBcAg VLP and conjugated with folic acid (FA) to produce FA-tHBcAg-PshRNA VLP. Electron microscopy revealed that the FA-tHBcAg-PshRNA VLP has an icosahedral structure that is similar to the unmodified tHBcAg VLP. Delivery of FA-tHBcAg-PshRNA VLP into HeLa cells overexpressing the folate receptor significantly downregulated the expression of anti-apoptotic Bcl-2 at 48 and 72 h post-transfection. The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay demonstrated that the cells' viability was significantly reduced from 89.46% at 24 h to 64.52% and 60.63%, respectively, at 48 and 72 h post-transfection. As a conclusion, tHBcAg VLP can be used as a carrier for a receptor-mediated targeted delivery of a therapeutic plasmid encoding shRNA for gene silencing in cancer cells.
    Matched MeSH terms: Hepatitis B virus*
  14. Is tenofovir the answer to further preventing mother-to-child transmission of hepatitis B?
    Abdul Hafidz MI, Tan SS, Lee YY
    J R Coll Physicians Edinb, 2016 12;46(4):248-250.
    PMID: 28504780 DOI: 10.4997/JRCPE.2016.409
    Matched MeSH terms: Hepatitis B; Hepatitis B, Chronic
  15. Perinatal transmission of hepatitis B virus - its significance
    Kuppuvelumani P
    Family Physician, 1991;3:39-41.
    Mass vaccination of all newborns against hepatitis B virus infection has been implemented in Malaysia since January 1989. The significance of perinatal transmission of hepatitis B virus and the prevention of the disease are discussed. Routine screening of 6443 mothers in the University Hospital showed an overall carrier rate of 1.9%; whilst this was high amongst the Chinese (4.7%), a significant number of Malays were also infected (1.6%). The mechanism of perinatal transmission of hepatitis B and the important role of routine screening of antenatal mothers in eradicating the disease are discussed.
    Matched MeSH terms: Hepatitis B; Hepatitis B virus
  16. Fulltext APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
    Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al.
    Hepatol Int, 2021 Oct;15(5):1031-1048.
    PMID: 34427860 DOI: 10.1007/s12072-021-10239-x
    BACKGROUND & AIM: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation.

    METHODS: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation.

    RECOMMENDATIONS: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

    Matched MeSH terms: Hepatitis B Surface Antigens; Hepatitis B virus
  17. Fulltext Chronic Viral Hepatitis in Malaysia: "Where are we now?"
    Raihan R, Mohamed R, Radzi Abu Hassan M, Md Said R
    Euroasian J Hepatogastroenterol, 2017 Jan-Jun;7(1):65-67.
    PMID: 29201775 DOI: 10.5005/jp-journals-10018-1214
    Malaysia is a country where an estimated 1 million people are chronically infected with hepatitis B virus (HBV) and an estimated 2.5% of the adult population are positive for antibody to hepatitis C virus (HCV). Effective nationwide vaccine coverage seems to be a highly effective measure to prevent new HBV infection. Treatment of HCV infection is also a regular practice in Malaysia. These measures highlight the possibility to reach the World Health Organization elimination target by 2030. To achieve this target, the Health Ministry and other nongovernmental organizations, such as My Commitment to Cure (MyC2C) are working together to develop a strategic road map to reach the global elimination target in Malaysia by 2030. How to cite this article: Raihan R, Mohamed R, Hasan MRA, Rosaida MS. Chronic Viral Hepatitis in Malaysia: "Where are we now?" Euroasian J Hepato-Gastroenterol 2017;7(1):65-67.
    Matched MeSH terms: Hepatitis B; Hepatitis B virus
  18. Delta hepatitis in Malaysia
    Sinniah M, Dimitrakakis M, Tan DS
    Southeast Asian J Trop Med Public Health, 1986 Jun;17(2):229-33.
    PMID: 3787309
    Sera from one hundred and fifty nine Malaysian individuals were screened for the prevalence of delta markers. These included 15 HBsAg positive homosexuals, 16 acute hepatitis B cases, 9 chronic hepatitis B patients, 13 healthy HBsAg carriers and 106 intravenous (i.v.) drug abusers, of whom 27 were positive for HBsAg only and the rest were anti-HBc IgG positive but HBsAg negative. The prevalence of delta markers in the homosexuals was found to be 6.7%, in the HBsAg positive drug abusers 17.8%, in acute hepatitis B cases 12.5%. No evidence of delta infection was detected in healthy HBsAg carriers, chronic hepatitis B cases and HBsAg negative i.v. drug abusers. With reference to i.v. drug abusers, the prevalence of delta markers was higher in Malays (23%) than in Chinese (7%) although the latter had a higher HBsAg carrier rate. Although the HBsAg carrier rate in the homosexuals was high, their delta prevalence rate was low as compared to drug abusers. In Malaysia, as in other non-endemic regions, hepatitis delta virus transmission appeared to occur mainly via the parenteral and sexual routes. This is the first time in Malaysia that a reservoir of delta infection has been demonstrated in certain groups of the population at high risk for hepatitis B.
    Matched MeSH terms: Hepatitis B/complications*; Hepatitis B Antibodies/analysis; Hepatitis B Antigens/analysis; Hepatitis B Surface Antigens/analysis
  19. Fulltext Pathway to global elimination of hepatitis B: HBV cure is just the first step
    Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, et al.
    Hepatology, 2023 Sep 01;78(3):976-990.
    PMID: 37125643 DOI: 10.1097/HEP.0000000000000430
    Hepatitis B (HBV) is a major cause of global morbidity and mortality, and the leading cause of liver cancer worldwide. Significant advances have recently been made toward the development of a finite HBV treatment that achieves permanent loss of HBsAg and HBV DNA (so-called "HBV cure"), which could provide the means to eliminate HBV as a public health threat. However, the HBV cure is just one step toward achieving WHO HBV elimination targets by 2030, and much work must be done now to prepare for the successful implementation of the HBV cure. In this review, we describe the required steps to rapidly scale-up future HBV cure equitably. We present key actions required for successful HBV cure implementation, integrated within the World Health Organization (WHO) Global Health Sector Strategy (GHSS) 2022-2030 framework. Finally, we highlight what can be done now to progress toward the 2030 HBV elimination targets using available tools to ensure that we are preparing, but not waiting, for the cure.
    Matched MeSH terms: Hepatitis B Surface Antigens; Hepatitis B virus
  20. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence
    Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, et al.
    Gut, 2012 Dec;61(12):1744-53.
    PMID: 22267593 DOI: 10.1136/gutjnl-2011-301281
    To investigate the molecular basis of occult hepatitis B virus (HBV) infection (OBI) in Asian blood donors.
    Matched MeSH terms: Hepatitis B Surface Antigens/genetics; Hepatitis B Surface Antigens/metabolism; Hepatitis B virus/genetics*; Hepatitis B virus/immunology; Hepatitis B virus/isolation & purification; Hepatitis B, Chronic/diagnosis; Hepatitis B, Chronic/immunology; Hepatitis B, Chronic/virology*
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links